Stock Price

Excelerate Energy signals deep confidence with a new $75M share buyback, balancing shareholder rewards with an ambitious global expansion in the LNG market.

A routine filing reveals a major strategic play. See how BridgeBio Oncology uses special equity grants to attract top minds in the fierce race for a cancer cure.

Argan's repeated dividend hikes and record backlog reflect deep confidence, positioning it to capitalize on surging demand for critical energy infrastructure.

MMTEC dodged delisting, but a one-year Nasdaq monitor and a history of reverse splits raise questions about its long-term viability on US exchanges.

A Delaware Supreme Court ruling revives a massive liability risk for Loews, extending a seven-year legal battle over its 2018 Boardwalk Pipelines deal.

A rival bid reshaped a major gold merger, creating a West African powerhouse. Here’s how the deal was saved and what it means for the market.

After major setbacks, a surge of innovative drugs is set to transform the ALS market. We decode the science, the money, and what it means for patients.

USA Rare Earth is accelerating its timeline to mine critical minerals by two years. Can innovative tech and bold strategy break foreign supply chain dominance?

Following stellar clinical data, Terns Pharmaceuticals' upsized $650M offering signals massive investor confidence and funds its push to disrupt the CML market.

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

GoldMining Inc. renews its flexible financing tool to tap the market. We analyze the strategy, the projects at stake, and the dilution dilemma for investors.

Protara Therapeutics secured a $75M offering to advance its promising cancer drug, TARA-002, signaling renewed investor confidence in biotech innovation.

Alerus Financial’s 5% dividend increase isn’t just a payout; it’s a story of strategic diversification and resilience in a volatile banking sector.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.

A promising fintech's complex arbitrage strategy collapses, triggering a stock crash, CEO exit, and a wave of securities fraud investigations.